A provider briefing on the Aurovela Fe 1/20 availability situation in 2026: timeline, prescribing implications, alternatives, and tools.
If your patients are reporting difficulty filling prescriptions for Aurovela Fe 1/20 (Norethindrone Acetate 1 mg / Ethinyl Estradiol 20 mcg / Ferrous Fumarate 75 mg, 28-day pack), you're hearing a real and ongoing problem. While Aurovela Fe 1/20 is not listed on the FDA Drug Shortage database, the practical availability of this specific generic at many retail pharmacies has been inconsistent since 2022.
This briefing covers the timeline, prescribing implications, current availability landscape, and tools to help your patients maintain uninterrupted access to contraception.
In mid-2022, patients began reporting that Walgreens pharmacies were telling them Aurovela Fe 1/20 was "discontinued." In reality, the drug remained FDA-approved and in active production by Aurobindo Pharma. Walgreens had shifted its preferred generic for the Norethindrone Acetate/Ethinyl Estradiol 1/20 formulation, leading to stock removal at many locations.
Supply chain disruptions affecting multiple generic oral contraceptive manufacturers led to intermittent shortages across several brands in this formulation class. CVS removed Aurovela from its preferred drug lists in certain regions in 2024, compounding availability challenges for patients specifically prescribed the Aurovela brand.
Manufacturing output from Aurobindo has stabilized, but distribution remains uneven. The primary issue in 2026 is not manufacturing capacity but rather pharmacy purchasing decisions — many chain pharmacies have locked into contracts with competing generic manufacturers (Teva for Junel, Lupin for Blisovi, Novitium for Larin), effectively removing Aurovela from their shelves.
One of the most impactful steps prescribers can take is to write prescriptions using the generic chemical name rather than a specific brand:
When a prescription specifies a brand name, some state pharmacy regulations and insurance systems may require that exact product. A generic-name prescription allows the dispensing pharmacist to fill with whichever AB-rated equivalent is in stock — Aurovela, Junel Fe 1/20, Microgestin Fe 1/20, Blisovi Fe 1/20, or Larin Fe 1/20.
All FDA-approved generics of Norethindrone Acetate/Ethinyl Estradiol 1 mg/20 mcg with Ferrous Fumarate are rated AB by the FDA, meaning they meet bioequivalence standards. Clinically, switching between these generics should not affect contraceptive efficacy. However, some patients may report subjective differences in side effects during the first 1-2 cycles after a switch, likely related to differences in inactive ingredients.
Unless a patient has a documented adverse reaction to a specific generic formulation's inactive ingredients (e.g., a dye allergy), avoid marking prescriptions as "Dispense as Written" (DAW) for this medication. DAW designations significantly limit the pharmacist's ability to fill the prescription when the specified brand is unavailable.
Based on pharmacy inventory data and patient reports in early 2026:
Independent pharmacies and mail-order pharmacies generally have more flexibility in sourcing specific brands through multiple distributors.
Under the ACA contraceptive mandate, most insurance plans must cover FDA-approved oral contraceptives without cost-sharing. This applies to all generic versions of Norethindrone Acetate/Ethinyl Estradiol 1/20. Key cost data for uninsured or underinsured patients:
For detailed pricing information to share with patients, refer them to our guide on saving money on Aurovela Fe 1/20.
Medfinder for Providers offers real-time pharmacy inventory search that can help your clinical staff locate in-stock pharmacies for patients at the point of prescribing. By checking availability before the patient leaves your office, you can proactively direct them to a pharmacy that has their medication.
Consider sharing these resources with patients who are having difficulty filling their prescriptions:
For patients in areas with persistent availability gaps, telehealth contraception services (e.g., Pandia Health, Nurx, SimpleHealth) maintain pharmacy partnerships designed for consistent supply chain access. These can be particularly useful for patients in rural or underserved areas.
The availability landscape for generic oral contraceptives continues to evolve. Key trends to watch in 2026:
The Aurovela Fe 1/20 availability issue is a distribution and formulary problem, not a manufacturing crisis. The most effective intervention prescribers can make is writing generic-name prescriptions that give pharmacists maximum flexibility. Combined with proactive availability checking through tools like Medfinder for Providers, you can help ensure your patients maintain uninterrupted access to their contraception.
For a practical workflow guide, see our companion article: How to help your patients find Aurovela Fe 1/20 in stock.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
